Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex Pharmaceuticals (VRTX) has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $10 billion, or $85 per share in cash. The deal is expected to close by the third quarter of 2026 and will expand Vertex's rare disease pipeline with assets like PALSONIFY and Atumelant. While analysts have not yet rerated VRTX shares post-announcement, H.C. Wainwright maintains a Buy rating.
Topics: biotech pharmaceuticals pipeline expansion rare diseases